Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 5/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158801 | 0.85 | ALOX5 (0.51) | ALOX5KMT2AHPGDMEN1POLB | |
| SCHEMBL7077550 | 0.85 | LMNA (0.51) | ALOX5KMT2AHPGDMEN1RAB9A | |
| SCHEMBL29130679 | 0.85 | ALOX5 (0.44) | ALOX5KMT2AHPGDMEN1POLB | |
| SCHEMBL11431832 | 0.85 | ALOX5 (0.44) | ALOX5KMT2AHPGDMEN1POLB | |
| SCHEMBL11433089 | 0.84 | ALOX5 (0.43) | ALOX5KMT2AHPGDMEN1POLB | |
| Potassium Ion SCHEMBL11433091 | 0.82 | PTGER1 (0.44) | ALOX5KMT2AHPGDMEN1POLB | |
| SCHEMBL6356334 | 0.82 | ALOX5 (0.46) | ALOX5KMT2AHPGDMEN1POLB | |
| SCHEMBL28311788 | 0.82 | HPGD (0.57) | ALOX5KMT2AHPGDMEN1RAB9A | |
| SCHEMBL11437319 | 0.82 | ALOX5 (0.49) | ALOX5KMT2AHPGDMEN1POLB | |
| SCHEMBL7830529 | 0.80 | ERCC5 (0.59) | ALOX5KMT2APOLBHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023246876-A1 | MEDICAL USE OF FORMAMIDE DERIVATIVES, FORMAMIDE DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 上海科技大学 | 2023-12-28 | — | — | WO | disclosed |
| US-20220289727-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-09-15 | — | — | US | disclosed |
| EP-4017850-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| CN-114258392-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-03-29 | — | — | CN | disclosed |
| WO-2021032938-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032935-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032935-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032938-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| US-10188910-B2 | Golf ball | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20180126226-A1 | GOLF BALL | DUNLOP SPORTS CO. LTD. (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20180056137-A1 | GOLF BALL | DUNLOP SPORTS CO. LTD. (JP) | 2018-03-01 | — | — | US | disclosed |
| US-9533195-B2 | Golf ball | DUNLOP SPORTS CO. LTD. (JP) | 2017-01-03 | — | — | US | disclosed |
| US-20160144241-A1 | GOLF BALL | DUNLOP SPORTS CO. LTD. (JP) | 2016-05-26 | — | — | US | disclosed |
| US-9283439-B2 | Golf ball | DUNLOP SPORTS CO., LTD. (JP) | 2016-03-15 | — | — | US | disclosed |
| US-20140206476-A1 | GOLF BALL | DUNLOP SPORTS CO. LTD. (JP) | 2014-07-24 | — | — | US | disclosed |
| EP-1532134-B1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | AVENTIS PHARMA SA (FR) | 2008-06-04 | — | — | EP | disclosed |
| EP-1532134-A1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | Aventis Pharma S.A. (FR) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004007477-A1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | WO | disclosed |
| US-4282246-A | Antidiabetic furancarboxylic and thiphenecarboxylic acids | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289727-A1 | ENZYME INHIBITORS | SERPINB1, ACE, GAA | ALOX5 1284/4885KMT2A 2768/4885HPGD 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.